Search: WFRF:(Blessborn Daniel) > (2015-2016) > Population pharmaco...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03824naa a2200469 4500 | |
001 | oai:DiVA.org:du-23296 | |
003 | SwePub | |
008 | 161028s2016 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:du-232962 URI |
024 | 7 | a https://doi.org/10.1093/infdis/jiw3382 DOI |
040 | a (SwePub)du | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Tchaparian, E.4 aut |
245 | 1 0 | a Population pharmacokinetics and pharmacodynamics of lumefantrine in young Ugandan children treated with artemether-lumefantrine for uncomplicated malaria |
264 | c 2016-07-28 | |
264 | 1 | b Oxford University Press (OUP),c 2016 |
338 | a electronic2 rdacarrier | |
520 | a Background. The pharmacokinetics and pharmacodynamics of lumefantrine, a component of the most widely used treatment for malaria, artemether-lumefantrine, has not been adequately characterized in young children. Methods. Capillary whole-blood lumefantrine concentration and treatment outcomes were determined in 105 Ugandan children, ages 6 months to 2 years, who were treated for 249 episodes of Plasmodium falciparum malaria with artemether-lumefantrine. Results. Population pharmacokinetics for lumefantrine used a 2-compartment open model with first-order absorption. Age had a significant positive correlation with bioavailability in a model that included allometric scaling. Children not receiving trimethoprim-sulfamethoxazole with capillary whole blood concentrations <200 ng/mL had a 3-fold higher hazard of 28-day recurrent parasitemia, compared with those with concentrations >200 ng/mL (P =. 0007). However, for children receiving trimethoprim-sulfamethoxazole, the risk of recurrent parasitemia did not differ significantly on the basis of this threshold. Day 3 concentrations were a stronger predictor of 28-day recurrence than day 7 concentrations. Conclusions. We demonstrate that age, in addition to weight, is a determinant of lumefantrine exposure, and in the absence of trimethoprim-sulfamethoxazole, lumefantrine exposure is a determinant of recurrent parasitemia. Exposure levels in children aged 6 months to 2 years was generally lower than levels published for older children and adults. Further refinement of artemether-lumefantrine dosing to improve exposure in infants and very young children may be warranted. © 2016 The Author. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicin0 (SwePub)3022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicine0 (SwePub)3022 hsv//eng |
653 | a Malaria; population pharmacokinetics; lumefantrine; artemisinin combination therapy; antimalarial; nonlinear mixed effects modeling; pharmacodynamics; trimethoprim-sulfamethoxazole | |
653 | a Hälsa och välfärd | |
653 | a Health and Welfare | |
700 | 1 | a Sambol, N.C.4 aut |
700 | 1 | a Arinaitwe, E.4 aut |
700 | 1 | a McCormack, S.A.4 aut |
700 | 1 | a Bigira, V.4 aut |
700 | 1 | a Wanzira, H.4 aut |
700 | 1 | a Blessborn, Daniel4 aut |
700 | 1 | a Bergqvist, Yngveu Högskolan Dalarna,Medicinsk vetenskap4 aut0 (Swepub:du)ybq |
700 | 1 | a Aweeka, F.T.4 aut |
700 | 1 | a Parikh, S.4 aut |
710 | 2 | a Högskolan Dalarnab Medicinsk vetenskap4 org |
773 | 0 | t Journal of Infectious Diseasesd : Oxford University Press (OUP)g 214:8, s. 1243-1251q 214:8<1243-1251x 0022-1899x 1537-6613 |
856 | 4 | u https://doi.org/10.1093/infdis/jiw338y Fulltext |
856 | 4 | u https://du.diva-portal.org/smash/get/diva2:1040768/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 | u https://academic.oup.com/jid/article-pdf/214/8/1243/17412244/jiw338.pdf |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:du-23296 |
856 | 4 8 | u https://doi.org/10.1093/infdis/jiw338 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Copy and save the link in order to return to this view